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Abstract: Purpose: To report visual acuity, contrast sensitivity and color vision prior to, 1 year after, 2 years after and 3 
years after iodine-125 brachytherapy for choroidal and ciliary body melanoma (CCM). 
Design: Prospective interventional case series. 
Participants: Thirty-seven patients (37 eyes) with CCM. 
Methods: Patients had best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity, Pelli-Robson 
contrast sensitivity and Hardy-Rand-Rittler color vision measurement; comprehensive ophthalmology examination; 
optical coherence tomography; and ultrasonography at baseline prior to, 1 year after, 2 years after and 3 years after I-125 
brachytherapy. 
Main Outcome Measures: Visual acuity, contrast sensitivity and color vision prior to, 1 year after, 2 years after and 3 
years after brachytherapy. 
Results: Nineteen (19) men and 18 women with mean age of 58 years (SD 13, range 30-78) prior to, 1 year after, 2 years 
after and 3 years after brachytherapy had mean best-corrected visual acuity of 77 letters (20/32), 65 letters (20/50), 56 
letters (20/80) and 47 letters (20/125); contrast sensitivity of 30, 26, 22 and 19 letters; color vision of 26, 20, 17 and 14 
test figures, respectively. Decrease in visual acuity, contrast sensitivity and color vision was statistically significant from 
baseline at 1 year, 2 years, and 3 years after brachytherapy. Decreased acuity at 3 years was associated with mid-choroid 
and macula melanoma location, ≥ 4.1 mm melanoma height, radiation maculopathy and radiation optic neuropathy. 
Conclusion: 1, 2 and 3 years after brachytherapy, eyes with CCM had significantly decreased visual acuity, contrast 
sensitivity and color vision. 
Keywords: Brachytherapy, choroidal melanoma, ciliary body melanoma, contrast sensitivity, visual acuity. 
INTRODUCTION 
 Choroidal and ciliary body melanoma (CCM) is the most 
common primary intraocular malignancy in adults. Overall 
incidence of uveal melanoma is reported as approximately 
5.1 per million per year in the United States [1]. 
 The Collaborative Ocular Melanoma Study (COMS) 
randomized clinical trial of iodine-125 (I-125) brachytherapy 
versus enucleation for medium-sized choroidal melanoma 
(2.5 – 10.0 mm in thickness and ≤ 16.0 mm in diameter) 
showed that, for patients who met the eligibility criteria, 
there was no statistically significant difference in all-cause 
mortality between I-125 brachytherapy and enucleation 5, 10 
and 12 years following treatment [2-4]. 
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 The COMS trial supported the use of globe-conserving I-
125 brachytherapy. However, adverse effects of I-125 
brachytherapy included dry eye and keratopathy, iris 
neovascularization and glaucoma, radiation cataract, 
radiation maculopathy and radiation optic neuropathy [5-11]. 
Reflecting these adverse effects, the COMS reported median 
visual acuity following I-125 brachytherapy for medium-
sized choroidal melanoma in 623 patients (623 eyes) as 
20/32 at baseline prior to brachytherapy and 20/125 3 years 
after brachytherapy [5]. 
 This current study was carried out, in accordance with a 
previously reported protocol [12], to further evaluate the 
effect of I-125 brachytherapy for CCM on central visual 
function by measurement of best-corrected visual acuity, 
contrast sensitivity and color vision prior to, 1 year after, 2 
years after, and 3 years after brachytherapy. 
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MATERIALS AND METHODOLOGY 
 This prospective interventional case study was conducted 
in accordance with the Declaration of Helsinki and approved 
by the Institutional Review Board of the University of 
California, Los Angeles (UCLA). Informed consent was 
obtained from all patients and the study adhered to 
provisions of the United States Health Insurance Portability 
and Accountability Act of 1996. 
 Adult patients with CCM undergoing I-125 
brachytherapy were eligible to enroll unless there was ocular 
disease unrelated to melanoma affecting central visual 
function of either eye, prior radiation therapy to the head or 
medical condition likely to interfere with 3 year follow-up. 
Baseline evaluation was performed ≤ 30 days prior to 
brachytherapy and post-treatment evaluation was carried out 
1 year, 2 years and 3 years after brachytherapy. Pretreatment 
and post-treatment evaluation included protocol refraction 
immediately prior to each visual acuity, contrast sensitivity 
and color vision measurement; comprehensive ophthalmic 
examination; fundus photography; optical coherence 
tomography; and ultrasonography. Fluorescein angiography 
was performed at baseline and as clinically indicated 
thereafter. 
 Visual Acuity. After refraction performed in accordance 
with the COMS Protocol [13], best-corrected visual acuity 
was measured as the number of letters read with each eye at 
3.2 m (or at 1.6 m or 0.8 m if necessary) using the Ferris-
Bailey Early Treatment Diabetic Retinopathy Study 
(ETDRS) visual acuity chart (The Lighthouse, Inc., Long 
Island City, NY) with standardized lighting. Snellen 
equivalent acuities of the ETDRS score were calculated from 
COMS Chart 02 [13]. 
 Contrast Sensitivity. Contrast sensitivity was measured as 
the number of letters with decreasing contrast recognized 
with each eye on a standard luminance background [12, 13]. 
Contrast threshold was assessed at one meter with the Pelli-
Robson Contrast Sensitivity Chart (Clement Clark, Dayton, 
OH), using standardized lighting and +0.75 D add over the 
distance refraction. For acuities below 20/320, the chart 
distance was shortened so that the letters appeared at twice 
the acuity threshold. 
 Color Vision. Hardy-Rand-Rittler Pseudoisochromatic 
Color Test Plates, 4th Edition (Richmond Products, Inc., 
Albuquerque, NM), were used to assess color vision in each 
eye with standardized illumination at 0.75 m. and +1.25 D 
add over the distance vision. Correct responses to 28 
diagnostic figures were scored.   
 Iodine-125 Brachytherapy. I-125 brachytherapy for CCM 
has been described elsewhere [14, 15]. Briefly, melanomas 
were treated to a target dose of 85 Gy at the tumor apex. 
Gold plaques consistent with COMS standards covered the 
tumor base and a surrounding margin of 3 mm. Under 
monitored local anesthesia and akinesia achieved with 
retrobulbar block, partial or 360-degree conjunctival 
peritomy was performed, rectus muscles were isolated and 
detached with a hang-back suture when required for plaque 
placement. Tumor borders were localized with 
transillumination and confirmed with indirect 
ophthalmoscopy. Transscleral fine needle aspiration biopsy 
was performed for cytopathology and cytogenetic study. The 
plaque was secured in position with 5-0 Mersilene sutures 
and placement was confirmed with intraoperative B-scan 
ultrasonography. The plaque remained in place for the 
duration determined by radiation dosimetry calculations and 
was removed under monitored local anesthesia. 
 Statistical Analysis. Statistical analysis used SAS version 
9.1 (Cary, NC). Difference in visual acuity, contrast 
sensitivity and color vision from baseline to 1 year, 2 years, 
and 3 years after brachytherapy, and difference in visual 
acuity from baseline to three years for melanoma location, 
melanoma thickness, cataract, maculopathy and optic 
neuropathy were assessed with the Wilcoxon signed rank 
test. Association of maculopathy and optic neuropathy with 
radiation dose was evaluated with the Fisher exact test and 
the Kruskal-Wallis test. P-value < 0.05 was considered 
statistically significant. 
RESULTS 
 Thirty-seven patients (37 eyes) with CCM (TNIM 
Classification T2a and T2b) [16] consisted of 19 (52%) men 
and 18 (48%) women with mean age at brachytherapy of 58 
years (SD 13 years, range 30-78 years). Ethnicity was White 
33 (90%), Hispanic 2 (5%), and Asian 2 (5%). There were 
19 left eyes and 18 right eyes. 
 For all CCM eyes at baseline prior to, 1 year after, 2 
years after, and 3 years after brachytherapy, mean visual 
acuity was 77 letters (20/32), 65 letters (20/50), 56 letters 
(20/80) and 47 letters (20/125); contrast sensitivity was 30 
letters, 26 letters, 22 letters and 19 letters; color vision was 
26 figures, 20 figures, 17 figures and 14 figures, respectively 
(Table 1). Decrease in visual acuity, contrast sensitivity and 
color vision from baseline at 1 year, 2 years and 3 years was 
statistically significant (Table 1). 
 Furthermore, 1 year after, 2 years after and 3 years after 
brachytherapy, change in visual acuity was statistically 
significantly correlated with change in contrast sensitivity 
(Spearman correlation coefficient=0.87 (p<0.0001), 0.91 
(p<0.0001) and 0.90 (p<0.0001) respectively) and change in 
color vision (Spearman correlation coefficient=0.50 
(p=0.005), 0.79 (p=<0.0001) and 0.78 (p<0.0001) 
respectively). Therefore, decrease in visual acuity, contrast 
sensitivity and color vision were significantly correlated and 
generally declined simultaneously after brachytherapy. 
 At baseline, visual acuity was ≥ 20/20 in 15 (41%) eyes 
and ≤ 20/200 in 2 (5%) eyes. Three years after 
brachytherapy, visual acuity was ≥ 20/20 in 4 (11%) eyes 
and ≤ 20/200 in 15 (41%) eyes (Table 1). 
 Analysis of CCM location and visual acuity showed 
location-dependent vision loss. At baseline and 3 years after 
brachytherapy, ciliary body/anterior (pre-equatorial) choroid 
tumors (n = 8) had a mean visual acuity of 76 letters and 77 
letters respectively, mid-choroid tumors (n = 16) 85 letters 
and 44 letters, and macula tumors (n = 13) 66 letters and 32 
letters (Table 2). The decrease in visual acuity for ciliary 
body/anterior choroid tumors was not significant (p=0.41), 
whereas mid-choroid and macula tumors had statistically 
significant change in visual acuity (p=0.002 and 0.006 
respectively). 
Vision After Melanoma Brachytherapy The Open Ophthalmology Journal, 2015, Volume 9    133 
 Melanoma apical height and visual acuity loss showed a 
significant correlation for thicker tumors. Melanomas with 
apical height of ≤ 4.0 mm (n = 21) had a mean visual acuity 
decrease from 79 letters to 58 letters, a decrease of 
borderline statistical significance (p=0.051), whereas 
melanomas ≥ 4.1 mm in apical height (n = 16) had a mean 
decrease from 74 letters to 35 letters, a decrease that was 
statistically significant (p<0.0001, Table 2). 
 Radiation Cataract, Maculopathy and Optic Neuropathy. 
Radiation cataract, defined as visually significant 
progression of 2+ or greater lens opacity compared to the 
fellow eye, developed in 13 (41%) of 32 eyes phakic at time 
of brachytherapy and was associated with significant 
decrease in mean visual acuity from 72 letters at baseline to 
31 letters 3 years after brachytherapy (p=0.008). This 
decrease in visual acuity in eyes with cataract was somewhat 
greater than the decrease in eyes aphakic at baseline or 
without cataract 3 years after brachytherapy, but the 
difference was not statistically significant (p=0.36). This is 
consistent with the practice of cataract surgery when 
clinically indicated. 
 Radiation maculopathy was identified by clinical 
abnormalities and, when indicated, by fluorescein 
angiography in 21 (57%) of 37 eyes and associated with a 
significant decrease in mean visual acuity from 72 letters at 
baseline to 27 letters 3 years after brachytherapy (p<0.0001). 
 Radiation optic neuropathy was diagnosed on the basis of 
optic disc pallor in 4 (11%) of 37 eyes and associated with 
severe decrease in vision from 45 letters at baseline to <1 
letter 3 years after brachytherapy, a decrease that was 
clinically but not statistically significant in this limited 
sample (p=0.13). 
 Fellow Eye Visual Function. The 37 unaffected fellow 
eyes had a baseline mean best-corrected visual acuity of 90 
letters (20/16), contrast sensitivity of 35 letters, and color 
vision of 28 figures, measurements that were significantly 
better than the corresponding baseline measurements in 
CCM eyes (p<0.0001, 0.0001 and 0.005 respectively). Three 
years after brachytherapy, mean best-corrected visual acuity 
in fellow eyes remained at 90 letters (20/16). 
Table 1. Visual acuity, contrast sensitivity and color vision three years after iodine-125 brachytherapy. 
 
Central Vision Baseline 1 Year 2 Years 3 Years 
Visual Acuity n % n % n % n % 
≥20/20 15 40.5% 8 21.6% 7 18.9% 4 10.8% 
20/25-20/40 10 27.0% 15 40.5% 10 27.0% 11 29.7% 
20/50-20/160 10 27.0% 8 21.6% 9 24.3% 7 18.9% 
≤20/200 2 5.4% 6 16.2% 11 29.7% 15 40.5% 
Mean+/-SD letters 76.7+/-20.2 (20/32) 65.3+/-28.0 (20/50) 55.6+/-34.6 (20/80) 46.6+/-37.2 (20/125) 
P-value 
  
0.001 
 
<0.0001 
 
<0.0001 
 
Contrast Sensitivity Letters 
Mean+/-SD 30.4+/-6.4 25.8+/-11.8 22.3+/-13.2 18.6+/-15.2 
P-value 
  
0.005 
 
<0.0001 
 
<0.0001 
 
Color Plates 
Mean+/-SD 25.6+/-5.4 19.6+/-11.8 16.8+/-12.6 13.6+/-13.2 
P-value 
  
0.001 
 
<0.0001 
 
<0.0001 
 
Table 2. Melanoma location, melanoma apical height and visual acuity outcome. 
 
 
Visual Acuity: Mean+/SD (Letters) 
P-Value* 
Baseline 1 Year 2 Years 3 Years 
Melanoma Location 
CB/Anterior, n=8 76.4+/-21.9 78.3+/-10.6 76.9+/-13.0 77.3+/-12.7 0.41 
Mid choroid, n=16 85.5+/-15.7 72.5+/-21.0 61.1+/-34.8 43.6+/-41.1 0.002 
Macula, n=13 66.2+/-20.3 48.5+/-35.3 35.7+/-34.6 31.8+/-33.5 0.006 
Melanoma Apical Height 
≤4.0 mm, n=21 78.8+/-16.5 72.9+/-22.9 64.4+/-33.0 58.2+/-37.4 0.051 
≥4.1 mm, n=16 74.0+/-24.5 55.4+/-31.6 44.1+/-34.2 34.9+/-34.3 <0.0001 
* CB/Anterior = ciliary body (3) and anterior (pre-equatorial) choroid (5). 
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DISCUSSION 
 This study of best-corrected visual acuity, contrast 
sensitivity and color vision prior to, 1 year after, 2 years 
after, and 3 years after globe-conserving I-125 brachytherapy 
for CCM provided new information regarding important 
parameters of brachytherapy-related vision impairment, 
confirmed major risk factors for brachytherapy-related vision 
loss and compared vision parameters in CCM eyes with 
corresponding measurements in unaffected fellow eyes. 
 For the first time, to our knowledge, contrast sensitivity 
and color vision measurement were systematically combined 
with assessment of best-corrected visual acuity to 
demonstrate the extent of central vision impairment 
following brachytherapy for uveal melanoma. Snellen visual 
acuity alone is insufficient for full understanding of visual 
performance. Decrease in contrast sensitivity and color 
perception measure distinctly different properties of vision 
and combine with impairment of visual acuity to interfere 
with activities of daily living such as mobility at low levels 
of illumination, perception of stairs and curbs, driving, 
reading, using tools and sewing [17-19]. This multi-faceted 
impairment of vision is particularly significant in patients 
with CCM and brachytherapy in the better-seeing eye and in 
patients with subsequent loss of vision in the better-seeing 
fellow eye. 
 Of practical importance, change in visual acuity, contrast 
sensitivity and color vision was statistically significantly 
correlated at 1 year, 2 years and 3 years after brachytherapy. 
Thus, visual acuity, contrast sensitivity and color vision 
generally declined simultaneously in the period after 
brachytherapy. 
 Concerning prognosis, this study confirmed several risk 
factors for brachytherapy-related vision loss reported in other 
studies [5, 6, 20, 21]. For example, this study of 37 patients 
(37 eyes) with CCM treated with I-125 brachytherapy 
reported mean visual acuity at baseline, 1 year, 2 years, and 
3 years after brachytherapy as 20/32, 20/50, 20/80 and 
20/125 respectively (Table 1). The COMS report of 623 
patients (623 eyes) with choroidal melanoma treated with I-
125 brachytherapy described median visual acuity at 
baseline, 1 year, 2 years, and 3 years after brachytherapy as 
20/32, 20/40, 20/50 and 20/125 respectively. In addition, this 
study and other reports identified greater risk of visual acuity 
loss associated with mid-choroid or macula tumor location, 
large tumor size, radiation maculopathy and radiation optic 
neuropathy (Table 2). These findings of visual acuity loss 
and relative risk for severe impairment of vision are useful in 
patient counseling and follow-up care. However, it should be 
noted that individual patients have a wide range of vision 
loss in response to brachytherapy and counseling should 
recognize individual variability. 
 Finally, comparison of the CCM eyes with fellow eyes in 
this study identified decrease in visual acuity, contrast 
sensitivity and color vision in CCM eyes prior to 
brachytherapy. Thus, impairment of central vision in 
melanoma eyes after brachytherapy is the result of both 
melanoma-related and brachytherapy-related central vision 
loss. Retention of normal vision in the fellow eyes 3 years 
after brachytherapy generally mitigated the functional impact 
of vision loss in the melanoma eyes and emphasized the 
importance of ophthalmologic care for the fellow eyes. 
 Relative strengths for this study of central vision in CCM 
eyes treated with brachytherapy are prospective design, 
protocol refraction prior to each assessment of central vision; 
measurement of best-corrected visual acuity, contrast 
sensitivity and color vision at baseline prior to, 1 year after, 2 
years after, and 3 years after brachytherapy; correlation with 
melanoma size and location; and corresponding 
measurements of central vision in the fellow eyes. Relative 
weakness is the limited sample size of 37 patients. 
 In summary, this study of 37 patients (37 eyes) with 
choroidal and ciliary body melanoma treated with I-125 
brachytherapy and followed for 3 years showed statistically 
significant and progressive mean decrease of best-corrected 
visual acuity, contrast sensitivity and color vision in the 
treated eyes. Greater decrease in visual acuity 3 years after 
brachytherapy was correlated with mid-choroidal and macula 
tumor location, baseline tumor height of ≥ 4.1 mm, radiation 
maculopathy and radiation optic neuropathy. 
CONFLICT OF INTEREST 
 The authors confirm that this article content has no 
conflict of interest. 
ACKNOWLEDGEMENTS 
 Authors acknowledge support by Research to Prevent 
Blindness Unrestricted Grant and the George and Ruth E. 
Moss Trust. 
REFERENCES 
[1] Singh AD, Turell MD, Topham AK. Uveal Melanoma: Trends in 
incidence, treatment, and survival. Ophthalmology 2011; 118: 
1881-5. 
[2] Diener-West M, Earle JD, Fine SL, et al. The COMS randomized 
trial of iodine 125 brachytherapy for choroidal melanoma. III. 
Initial mortality findings. COMS report no. 18. Arch Ophthalmol 
2001; 119: 969-82. 
[3] Collaborative Ocular Melanoma Study Group. Ten-year follow-up 
of fellow eyes of patients enrolled in Collaborative Ocular 
Melanoma Study randomized trials: COMS report no. 22. 
Ophthalmology 2004; 111: 966-76. 
[4] Collaborative Ocular Melanoma Study Group. The COMS 
randomized trial of iodine 125 brachytherapy for choroidal 
melanoma. V. Twelve-year mortality rates and prognostic factors. 
COMS report no. 28. Arch Ophthalmol 2006; 123: 1684-93. 
[5] Melia BM, Abramson DH, Albert DM, et al. Collaborative Ocular 
Melanoma Study (COMS) randomized trial of I-125 brachytherapy 
for medium choroidal melanoma. I. Visual acuity after 3 years. 
COMS report no. 16. Ophthalmology 2001; 108: 348-66. 
[6] Wen JC, Oliver SC, McCannel TA. Ocular complications 
following I-125 brachytherapy for choroidal melanoma. Eye 2001; 
23: 1254-68. 
[7] Detorakis ET, Engstrom Jr RE, Wallace R, et al. Iris and anterior 
chamber angle neovascularization after iodine 125 brachytherapy 
for uveal melanoma. Ophthalmology 2005; 112(3): 505-10. 
[8] Collaborative Ocular Melanoma Study Group. Incidence of cataract 
and outcomes after cataract surgery in the first 5 years after Iodine 
125 brachytherapy in the Collaborative Ocular Melanoma Study. 
COMS report no 27. Ophthalmology 2007; 114(7): 1363-71. 
[9] Horgan N, Shields CL, Mashayekhi A, et al. Classification and 
treatment of radiation maculopathy. Curr Opin Ophthalmol 2010; 
21: 233-8. 
[10] Mukai S, Guyer DR, Gragoudas ES. Radiation retinopathy. In: 
Albert DM, Jakobiec FA, Eds. Principles and practices of 
Vision After Melanoma Brachytherapy The Open Ophthalmology Journal, 2015, Volume 9    135 
ophthalmology: clinical practice W.B. Saunders Company 
Pennsylvania 1994; vol. 2: pp. 1038-41. 
[11] Kim IK, Lane AM, Egan KM, et al. Natural history of radiation 
papillopathy after proton beam irradiation of parapapillary 
melanoma. Ophthalmology 2010; 117(8): 1617-22. 
[12] Oliver SCN, Young TA, Kobe LH, et al. Assessment of central 
vision and macular structure in patients undergoing iodine-125 
brachytherapy for ciliochoroidal melanoma. Am J Clin Oncol 
2008; 31(5): 488-92. 
[13] Collaborative Ocular Melanoma Study Group. COMS manual of 
procedures. Virginia: National Technical Information Service 1995. 
[14] Young TA, Rao NP, Glasgow BJ, et al. Fluorescent in situ 
hybridization for monosomy 3 via 30-gauge fine-needle aspiration 
biopsy of choroidal melanoma in vivo. Ophthalmology 2007; 
114(1): 142-6. 
[15] McCannel TA, Burgess LB, Rao NP, et al. Identification of 
candidate tumor oncogenes by integrative molecular analysis of 
choroidal melanoma fine needle aspiration biopsy specimens. Arch 
Ophthalmol 2010; 128(9): 1170-7. 
[16] American Joint Committee on Cancer cancer staging manual, 7th  
ed. New York Dordrecht Heidelberg London: Springer 2010; pp. 
547-53. 
[17] Rubin GS, Bandeen-Roche K, Huang GH, et al. The association of 
multiple visual impairments with self-reported visual disability: 
SEE project. Invest Ophthalmol Vis Sci 2001; 42(1): 64-72. 
[18] Arden GB. The importance of measuring contrast sensitivity in 
cases of visual disturbance. Br J Ophthalmol 1978; 62(4): 198-209. 
[19] Colenbrander A, Fletcher DC. Beyond BCVA: Thorough vision 
assessment for retinal physicians Retinal Physician November - 
December 2011; 50-55. 
[20] Finger PT, Chin KJ, Guo-pei Y, et al. Risk factors for radiation 
maculopathy after ophthalmic plaque radiation for choroidal 
melanoma. Am J Ophthalmol 2010; 149(4): 608-15. 
[21] Sagoo MS, Shields CL, Emrich J, et al. Plaque radiotherapy for 
juxtapapillary choroidal melanoma; treatment complications and 
visual outcomes in 650 consecutive cases. JAMA Ophthalmol 
2014; 132(6): 697-702. 
 
 
Received: February 13, 2015 Revised: April 29, 2015 Accepted: May 11, 2015 
 
© Tsui et al.; Licensee Bentham Open. 
 
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) 
which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. 
